The NIH intramural research program has shifted all non-mission-critical laboratory operations to a maintenance phase in order to promote physical distancing and diminished transmission risk of COVID-19. Effective Monday, March 23, 2020, only mission-critical functions within NIH research laboratories will be supported.

What AMP SCZ Partners Are Saying

American Psychiatric Association Foundation

“Schizophrenia is a complex, sometimes debilitating, disorder that affects one percent of the population. While we’ve made strides in treating its symptoms over the years, more research and tools for physicians are needed to help our patients, particularly to identify and treat those who are at high risk for psychosis,” said Saul Levin, M.D., M.P.A., chair of the American Psychiatric Association Foundation. “The American Psychiatric Association Foundation is pleased to support the Accelerating Medicines Partnership for Schizophrenia, which brings together such a robust group of organizations from the public, nonprofit and private sectors to research biomarkers that will improve our success in treating those with this disorder.”

Boehringer Ingelheim

“At Boehringer Ingelheim, we are dedicated to advancing research to improve care for individuals impacted by neuropsychiatric diseases, including schizophrenia. Collaboration is a vital element to driving innovation in treatment approaches for these complex diseases of the brain. We believe by being a partner of the Accelerating Medicines Partnership for Schizophrenia along with the Foundation for the National Institutes of Health (FNIH), the National Institutes of Health (NIH) and other industry leaders, we will accelerate research and bring potential new treatment options to this patient population so greatly in need of more options.” - Dr. Vikas Mohan Sharma, Head of Medicine, CNS, Retinopathies & Emerging Areas, Boehringer Ingelheim, Germany

Janssen

“At Janssen, we recognize that diseases as complex as the brain require a comprehensive approach, centered on the unique needs, goals and circumstances of the individual patients, as well as the loved ones who support them. We are proud to be part of the Accelerating Medicines Partnership for Schizophrenia — a momentous collaboration with leading industry and non-profit partners who share our mission to deliver transformational medical innovations to those living with or at risk for schizophrenia and their loved ones.”- Bill Martin, Ph.D., Global Therapeutic Head, Neuroscience, Janssen Research & Development, LLC.  

National Alliance on Mental Illness

“NAMI was founded by parents of adult children with schizophrenia over 40 years ago and we’re proud to be a part of the of the Accelerating Medicines Partnership for Schizophrenia, a watershed moment in our field,” said Daniel H. Gillison, Jr., CEO of  the National Alliance on Mental Illness (NAMI). “This partnership is a new opportunity for coordinated research on the root causes and progression of schizophrenia, a complex, long-term medical illness. NAMI is dedicated to this partnership which represents the best of the public, private and academic communities. We can all agree that we need better treatments for psychosis and this partnership has the potential to fast-track progress in this area.”

One Mind

“One Mind is proud to participate in the Accelerating Medicines Partnership for Schizophrenia,” said Brandon Staglin, President, One Mind. “I’m thrilled this partnership will develop biomarkers and research infrastructure that will lead to new medicines that can restore years of life quality and potential to people who, like me, experience schizophrenia. Building on the twenty years of groundwork of two One Mind-supported NIMH programs, the opportunity to support this partnership is a dream come true.”

Otuska

“We are excited to partner with leaders in the private and public sectors towards the advancement of better-targeted interventions for people with serious mental illness,” said Christoph Koenen, Executive VP and Chief Medical Officer, Otsuka Pharmaceutical Development and Commercialization. “With AMP’s proven ability to leverage our collective skills, experiences and passions we believe this is an unprecedented opportunity to validate biomarkers for those at risk for early psychosis, and to accelerate the identification of new drug targets for schizophrenia.”

Wellcome 

“Wellcome is delighted to be involved in this important initiative. The goals of the AMP SCZ have the potential to transform the field of early intervention for psychosis and align with the vision of the Wellcome Innovations Psychosis Flagship to improve outcomes for patients with psychosis. Early intervention may change the trajectory of the disease leading to significant improvements in the lives of individuals with psychosis.” - Lynsey Bilsland, Ph.D., Deputy Head of Programme, Innovations, Wellcome 

This page last reviewed on September 15, 2020